Ying-Hui Tong
0000-0001-5060-3975
3 papers found
Refreshing results…
Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers’ perspective
Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial
Elevated proportion of collapsed microvessels indicate poor survival outcome in patients with non-small cell lung cancer
Missing publications? Search for publications with a matching author name.